分子诊断的共同研究及授权契约:2016年～2025年

"分子诊断领域的合作与许可交易" 报告提供了前所未有的途径，让我们能够全面了解全球领先生物製药公司达成的分子诊断交易。

本报告详细介绍了2016年至2025年的分子诊断交易，并详细解读和分析了企业达成分子诊断交易的方式和原因。这些交易往往涉及多个领域，从合作研发到成果商业化，应有尽有。

本报告涵盖了合作、开发、研究和授权交易。它提供了自 2016 年以来宣布的 759 笔分子诊断交易的综合清单。此外，它还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件（如有）。

本报告第一章介绍了分子诊断交易。

第一章是对报告的介绍。

第二章概述了自 2016 年以来的分子诊断交易活动。

第三章概述了自 2016 年以来的主要分子诊断交易。交易按标题价值列出。

第四章提供了在分子诊断交易中最活跃的 25 家公司的综合列表，随后是简要摘要和分子诊断交易的综合列表，以及上市公司可用的合约文件。

第五章全面深入地回顾了自2016年1月以来达成和宣布的分子诊断交易，并提供了公开的合约文件。

第六章全面深入地回顾了自2016年1月以来达成和宣布的分子诊断伙伴关係。本章按感兴趣的特定分子诊断技术类型进行组织。

此外，报告还包含大量图表和数据，展示了自2016年以来的分子诊断交易活动。

此外，综合交易目录按公司A-Z、交易类型和治疗目标进行组织。每个交易标题都透过网页连结连结到线上交易记录，并且（如有）还包含合约文件，方便在需要时轻鬆存取每份协议文件。

主要的优点

"分子诊断领域的合作与授权协议" 提供读者以下主要优势：

• 了解自2016年以来的交易趋势
• 浏览分子诊断领域的合作与授权交易
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 依公司A-Z、交易类型及治疗领域排列的交易目录
• 主要交易价值
• 最活跃的交易者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作公司
• 节省数百小时的研究时间

研究范围

• 分子 "分子诊断合作与授权协议" 旨在深入了解全球领先生物製药公司达成的分子诊断趋势和交易结构。

分子诊断合作与授权协议包括：

• 生物製药产业的分子诊断交易趋势
• 涵盖製药和生物技术领域的分子诊断交易记录目录
• 主要分子诊断交易
• 最活跃的分子诊断许可交易商
• "分子诊断合作与许可协议" 提供全面的交易记录存取权限，包括合约文件（如有）。

对协议进行分析有助于进行尽职调查：

• 授予或选择的具体权利是什么？
• 实际授予合约伙伴哪些权利？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权如何处理归属于谁？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更会怎样？
• 双方约定了哪些再授权和分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款在不同合作伙伴或不同交易类型之间似乎有所不同？
• 公司在契约法方面主张哪些管辖权？

目录

摘要整理

第1章 简介

第2章 分子诊断交易趋势

• 简介
• 多年的分子诊断交易
• 最活跃的分子诊断交易业者
• 分子诊断交易，类别
• 分子诊断交易，各治疗领域
• 分子诊断交易，各业界
• 分子诊断交易的交易条件
  • 分子诊断交易的标题价值
  • 分子诊断交易预付款
  • 分子诊断交易的里程金
  • 分子诊断权利金费率

第3章 -主要分子诊断交易

• 简介
• 分子诊断相关的首位交易额

第4章 -最活跃的分子诊断交易业者

• 简介
• 最活跃的分子诊断交易业者
• 最活跃的分子诊断交易企业简介

第5章 分子诊断契约交易名录

• 简介
• 分子诊断契约交易名录

第6章 各技术类型的分子诊断交易

• 交易名录
• 交易名录- 分子诊断交易(AZ)，各企业
• 交易名录- 分子诊断交易，各交易类型
• 交易名录- 分子诊断交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers
• Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2025
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers 2016 - 2025
• Figure 12: Molecular diagnostics deals by technology type since 2016